Search - tctmd.com

Displaying 1 - 20 of 433

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2025

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

Presenter: Alexandre Abizaid

October 25, 2025

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

Presentation TCT 2023

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: Usman Naseer

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2023

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Presenter: Giovanni Esposito

October 25, 2023

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

L.A. McKeown

May 31, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presenter: Jung-Min Ahn

September 19, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Presentation TCT 2021

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

Presenter: Pasi Karjalainen

November 06, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

DES Best for In-Stent Restenosis, but DCBs Also Viable

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

FDA Approves Bioresorbable Scaffold for BTK Lesions

Top Endovascular News of 2023

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content